Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co Days Payable Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Days Payable
2,347.08
194.98
125.47
186.77
214.89
Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
HKSE:06990 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co Days Payable vs Biotechnology Industry
Sichuan Kelun-Biotech Biopharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Days Payable of 315.10 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. This is 62% above median its historical median of 194.98. Over the past decade, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Payable has ranged from 125.47 to 2,347.08. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #222 out of 704 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Days Payable too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Payable of 315.10 is 62% above median its 10-year median of 194.98. Over the past 10 years, this metric has ranged from a low of 125.47 to a high of 2,347.08. The Biotechnology industry median Days Payable is 110.01. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 315.10 is 186.4% above this industry median. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #222 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #222 out of 704 companies for Days Payable. This puts Sichuan Kelun-Biotech Biopharmaceutical Co in the upper half of its industry. The industry median Days Payable is 110.01. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 315.10 is 186.4% above this benchmark. Historically, Sichuan Kelun-Biotech Biopharmaceutical Co's own Days Payable has ranged from 125.47 to 2,347.08 over the past decade. While the company's 10-year median is 194.98 vs. the industry median of 110.01, Sichuan Kelun-Biotech Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Payable of 315.10 is 186.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Payable is 315.10, which is 62% above median its own 10-year median of 194.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Days Payable is 315.10, which is 62% above median its 10-year median of 194.98 and 186.4% above the Biotechnology industry median of 110.01. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Days Payable is 315.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued.
The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91.
GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.
Key valuation signals for HKSE:06990:
Days Payable: 315.10 (62% above median its 10-year median of 194.98)
GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
Industry Position: 186.4% above the Biotechnology median (#222 of 704)
No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score
Get the complete analysis for HKSE:06990
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06990 has been successfully added to your 
